Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer

The cornerstone of treatment for advanced ALK-positive lung cancer is sequential therapy with increasingly potent and selective ALK inhibitors. The third-generation ALK inhibitor lorlatinib has demonstrated clinical activity in patients who failed previous ALK inhibitors. To define the spectrum of A...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Yoda, Satoshi, Lin, Jessica J., Lawrence, Michael S., Burke, Benjamin J., Friboulet, Luc, Langenbucher, Adam, Dardaei, Leila, Prutisto-Chang, Kylie, Dagogo-Jack, Ibiayi, Timofeevski, Sergei, Hubbeling, Harper, Gainor, Justin F., Ferris, Lorin A., Riley, Amanda K., Kattermann, Krystina E., Timonina, Daria, Heist, Rebecca S., Iafrate, A. John, Benes, Cyril H., Lennerz, Jochen K., Mino-Kenudson, Mari, Engelman, Jeffrey A., Johnson, Ted W., Hata, Aaron N., Shaw, Alice T.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5984716/
https://ncbi.nlm.nih.gov/pubmed/29650534
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-17-1256
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados